Health Care

Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Indian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust Complaint
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Indian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust Complaint
Philips Sues SoClean Alleging Ozone Exposure Risks Over Injuries Related To Breathing Devices
Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use

Health Care Recent News

Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.
Merck Ends Keytruda Combo Melanoma Study Due to Futility
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma.
Alimera Sciences Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis reversal.
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug.
Vaxart Stock Climbs After Blockbuster Q1 Revenue
Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year.
Insulet Q1 Earnings Top, 2024 Revenue View Raised
Insulet Corporation (NASDAQ: PODD) reported GAAP earnings per share of 73 cents for first-quarter 2024, which significantly improved from the year-ago period's EPS of 34 cents. The figure also exceeded the Zacks Consensus Estimate by 87.2%.
CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment
There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB). But, treatments to help alleviate and control the symptoms do exist. The growing body of research suggests cannabinoid-based medicines help ease pain and pruritus in those with a disorder while improving wound healing.The latest scientifically prove healing power of cannabis was Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products.
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers